COMPANY

Gengagon is delivering unprecedented opportunities to fight cancer. We develop the next generation of therapeutical antibody-drug conjugates with a unique target profile and the ability to treat solid tumors, where no successful standard of care treatments is available. Our pipeline focuses on a therapeutically novel transmembrane protein class accumulating on the surface of cancer cells and tumor promoting cells within the tumor.

THE COMPANYAbout Genagon

From company headquarters in Stockholm, Sweden, Genagon is researching, developing and clinically testing novel drug delivery proteins that offer extraordinary opportunities to fight a large variety of hitherto untreatable solid tumors. Our Antibody-Drug Conjugates are potent biopharmaceuticals that both kill cancer cells and pave the way for complete tumor clearance, thus significantly decreasing the risk of future relapses. Moreover, ADCs display not only high efficacy, they are also very cost-effective.

As an astute, goal-oriented company, we are committed to developing/advancing these new therapeutic opportunities into real clinical benefits and increased hope for cancer patients. Our patent portfolio is strong, and we receive sound financial support from major Swedish investors.

Vision

To increase treatment efficacy and periods of remission for cancer patients and in the future, give people a chance to live cancer-free.  

Mission

Provide next generation antibody drug conjugates for indications with high unmet clinical need

FROM THE CEO

Moa Fransson

Genagon identifies novel targets for antibody targeted therapy in cancer, working in the exciting emerging field of antibody drug conjugates.

We have a highly devoted and skilled team conducting research and development. We have a unique research competence in antibody validation and characterization that accelerates the selection process of our lead antibody assets. We have many collaborations worldwide, but at Genagon we coordinate and evaluate the important results. Our mission is to bring new therapies into the clinic and in the long run become one of the companies that contribute with new innovations and treatments in the fight against cancer.

There is an arising interest from the pharmaceutical sector and Genagon has got a lot of traction for our ADC assets in the breast cancer area. During the coming year we will start cell line development and the clinical production of our lead candidate ADC. Bringing the next generation of ADCs to the clinic is one important mission.

https://genagon.com/wp-content/uploads/2021/08/Genagon-bilder-3-scaled.jpg
The best part of Genagon is the highly devoted and skilled team of researchers conducting the research and development. We have a unique competence in antibody validation and characterization that accelerates the selection process of our lead antibody assets.
Moa Fransson
CEO, PhD

BACKGROUNDOur history

2015

2015

Genagon Therapeutics is founded based on a discovery at Uppsala University by Andries Blokzijl, MD, PhD. The first patent application filed. The first pre-clinical candidate GEN100 is generated.

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

2017

2017

The pre-clinical candidate GEN100 successfully eradicates tumors in a breast cancer mouse model.

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

2019

2019

The pre-clinical candidate GEN100 was cancelled due to unsatisfactory production yields and poor pharmacokinetics in mice. Partnership for antibody generation with Ligand Pharmaceutical launched. Genagon receives a Vinnova grant to improve response rates with antibody candidates.

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

2020

2020

Antibody generation program with natively folded antigen launched. Successful generation of therapeutic, fully human antibody clones achieved. A new type of target protein described, located to cancer cells and tumor associated macrophages.

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

2021

2021

Panel of monoclonal antibodies successfully validated. Initiation of the ADC program and selection of a lead candidate with excellent characteristics and efficacy in the targeted indication.

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]